mRNA-1010 is Moderna’s first seasonal influenza vaccine candidate to enter the clinic mRNA-1010 is a quadrivalent seasonal influenza vaccine candidate targeting WHO recommendations including A H1N1, H3N2 and influenza B Yamagata and Victoria lineages Moderna’s vision is to develop a respiratory vaccine for the adult and elderly populations combining seasonal flu, COVID-19 … [Read more...] about Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine
Approximately €400million investment annually to accelerate end-to-end R&D of next-generation vaccines, fully financed through resource reallocation Focus on innovating mRNA vaccines beyond pandemic to routine use in diseases with high unmet need Expected minimum of six clinical candidates by 2025 PARIS – Sanofi will invest approximately €400 million annually in a … [Read more...] about Sanofi launches dedicated vaccines mRNA Center of Excellence
The power of mRNA has been demonstrated on a global scale during the pandemic. But what would happen if people started using it for self-enhancement? Our imagined dispatch from the future https://t.co/IAkXsbIiTO— The Economist (@TheEconomist) June 27, 2021 … [Read more...] about What would happen if people started using mRNA for self-enhancement?